Abstract:Abstract Study question Does co-administration of GnRH agonist and Human chorionic gonadotropin(dual trigger) in PGT cycles improve the number of usable blastocysts per patient compared to hCG alone? Summary answer Using the dual trigger has no effect on the number of usable blastocysts undergoing the GnRH-ant protocol for PGT compared to triggering with hCG alone. What is known already HCG is used at the end of controlled ovarian hyperstimulation as a surrogate LH surge to induce final oocyte maturation. Recently, based on retrospective studies, the co-administration of GnRH agonist and hCG for final oocyte maturation (dual trigger) has been suggested to improve IVF outcome and pregnancy rates. Study design, size, duration A prospective, randomized, open-label controlled clinical trial (ChiCTR-ICR-2000031342), enrolled patients attending our university affiliated Infertility and IVF center (the Reproductive and Genetic Hospital of CITIC-Xiangya, China) between August 2020 and June 2021. This sample size achieves with a power of 80%, at a significance level(α) of 0.05. A sample size of 160 patients, 80 randomized to each group, was chosen to allow for those 10% dropped out. Participants/materials, setting, methods The inclusion criteria for participating were: women age 20–35years, AMH≥1.2ng/ml and /or AFC ≥5, Couples with PGT-SR preimplantation genetic testing for chromosomal structural rearrangements (patients with abnormal chromosomal structure only in male or female), undergoing one of their first PGT cycle attempts. Patients fulfilled the criteria on the trigger day were randomly assigned to receive hCG or the dual trigger for final oocyte maturation. The primary outcome was the number of usable blastocysts per patient. Main results and the role of chance 160 patients were included in the study. The age (29.1 years versus 29.4 years), BMI (22.1 kg/m2 versus 21.9 kg/m2) and the AMH (5.3 ng/ml versus 5.3 ng/ml) were comparable between the two groups. Based on PP analysis, there were no statistical difference in the number of eggs retrieved (17.1 versus 15.9), the MII oocytes (13.3 versus 12.5), the number of usable blastocysts per patient (5.0 versus 4.6) and top-quality blastocysts per patient (3.4 versus 3.2) between the two groups. Limitations, reasons for caution None Wider implications of the findings The enhanced response observed with the dual trigger might lead to better IVF outcomes were it used more widely. Trial registration number ChiCTR-ICR-2000031342

Comparative Study of Full Dose and Half Dose of Decapeptyl in IVF

The clinical study of optimal dose of Decapeptyle for poor ovarian response patients in IVF-ET cycles.

The application of low dose Enantone in IVF-ET

DDDT_A_270519 3673..3682

[Gonadotropin-Releasing Hormone Antagonist Protocol in Patients with Risk of Poor Response to Ovarian Stimulation in IVF-ET].

Comparison of GnRH-a Prolonged Protocol and Short GnRH-a Long Protocol in Patients with Thin Endometrium for Assisted Reproduction: A Retrospective Cohort Study

Effects of Different Exposure Days to Gonadotropin-Releasing Hormone Agonist (Gnrh-A) on Live Birth Rates in the Depot GnRH-a Protocol: A Retrospective Analysis of 7007 Cycles

P-676 Comparison of Hcg Triggering Versus Hcg in Combination with a GnRH Agonist: a Prospective Randomized Controlled Trial

Clinical Application of Suboptimal Dose of Triptorelin in Ovarian Stimulation for IVF-ET

Comparison of the effect of short-acting and long-acting GnRH-a in IVF-ET by long protocol

Comparison of Clinical Effects of Different Kinds of Down-Regulation Protocols by Short-Acting Triptorelin in IVF/ICSI

Clinical effect of reduced dose gonadotropin releasing hormone agonist long protocol and gonadotropin releasing hormone antagonist protocol in patients with decreased ovarian reserve

Mini-dose GnRH-a Long Versus Short Protocol in Patients ≥ 35 Years Old Undergoing in Vitro Fertilization.

Effect of Pituitary Down-regulation of Long Protocol Controlled Ovarian Stimulation on the Outcome of in-vitro Fertilization and Embryo Transfer

Reducing the Trigger Dose of Human Chorionic Gonadotrophin Does Not Affect Final Oocyte Maturation and Subsequently Pregnancy Outcome of Frozen-thawed Embryo Transfer

[Application of GnRH-antagonist to IVF-ET for Patients with Poor Ovarian Response].

Impact of progesterone level after HCG administration on the outcome of IVF in long GnRH-agonist pituitary suppression protocol

Comparison of pregnancy outcome among double stimulations,mild stimulation and lutea-phase stimulation protocol in patients with diminished ovarian reserve

[Influence of Duration of Gonadotropin Administration on the Clinical Outcome of in Vitro Fertilization Embryo Transfer].

The Application of Long-Acting and Short-Acting Forms of Gonadotrophin-Releasing Hormone Agonists in Long Protocol of IVF/ICSI Cycles

Effect of improved super-long protocol on pregnancy outcome after treatment of standard longprotocol in infertility patients